GSK price forecast: strong quarter and technicals

Traders Union
All News
Financial News
GSK surges 6.75% today to $1,755

Highlights

GSK plc is trading at $1,755.00, well above its MA-20 ($1,634.85), MA-50 ($1,543.05), and MA-200 ($1,455.67), confirming strong bullish momentum.
GSK raised its 2025 turnover growth guidance to 6–7% following robust third-quarter results, providing a strong foundation for the incoming CEO's strategy.
Over the next five trading days, GSK is expected to fluctuate between $1,743.50 and $1,873.77, with more than 80% probability of further price gains.

Upbeat guidance and trade risks as financial results beat forecasts

GSK published its third-quarter results, reporting turnover growth of 6% to 7% for 2025 — an upward revision from the previous range. This stronger-than-expected performance highlights robust fundamentals, though the company also faces lingering trade uncertainties. These financial results are set to encourage the incoming CEO and may shape future strategy.

Strong technical signals with stretched momentum and high volatility

Momentum indicators show strength, with the daily MACD giving a strong buy signal even as the ADX signals a possible trend pause. RSI and CCI are in well-supported buy territory, but the Stoch RSI is oversold; this divergence hints at stretched near-term conditions. BBP is neutral, suggesting buyers do not fully dominate intraday, though the Awesome Oscillator supports the uptrend. There was a clear gap up from the previous close ($1,644.00) to today's open ($1,679.70) and price is currently trading near the session high. Intraday volatility is high, with strong upward tone and pronounced strength toward highs since the open.

Price consolidation likely as bullish odds dominate short term

For the next five trading days, the expected range is $1,743.50 to $1,873.77. There is a very high probability (more than 80%) of further price gain, while the chance of a decline is very low. The baseline scenario sees GSK fluctuating sideways within this corridor, absorbing recent gains. In a bullish scenario, a decisive push above $1,757.50 could open the way toward the $1,870s. A bearish turn would require a break below $1,569.75, exposing the stock to downside toward longer-term moving average supports.

Viktoras Karapetjanc, expert at Traders Union, views GSK’s sustained momentum above key moving averages and its strong Q3 earnings revision as clear evidence of improving investor confidence and resilient fundamentals. He believes macro and sentiment factors are aligned for near-term strength, especially as broader market conditions and corporate performance reinforce the bullish trend. The absence of immediate overhead technical resistance, coupled with high probability forecasts, supports a positive tactical outlook. "With fundamentals strengthening and momentum intact, I expect GSK to consolidate recent gains and attempt a breakout toward new highs in the coming sessions."

Previously it was noted that buyback activity and investor accumulation were offset by R&D pipeline risks, with volatility remaining low as the price consolidated in a narrow daily range. Technical indicators showed mixed momentum amid cautious sentiment driven by product developments and regulatory concerns, as highlighted in technical outlook signaled mixed momentum.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.